UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 13, 2017
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-35839 |
04-3205099 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
500 Arsenal Street, Watertown, Massachusetts 02472
|
||
|
(Address of principal executive offices and zip code)
|
||
|
(617) 607-0800 |
||
|
|
||
|
(Registrant’s telephone number, including area code)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
Appointment of Kristine Peterson to Board of Directors
On September 13, 2017, the Board of Directors of Enanta Pharmaceuticals, Inc. announced that Kristine Peterson had been elected to serve as an independent director of the Company in the class of directors whose terms expire at Enanta’s 2018 Annual Meeting of Stockholders. This election increases the number of directors to seven. The Board of Directors also appointed Ms. Peterson as a member of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors.
Ms. Peterson will receive the standard compensation for non-employee directors of Enanta, including retainer fees for Board and committee service and stock options, and will have the benefit of the Company’s standard form of indemnification agreement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
Date: September 13, 2017 |
|
By: |
/s/ Paul J. Mellett |
|
|
|
|
Paul J. Mellett |
|
|
|
|
Senior Vice President, Finance and Administration and Chief Financial Officer |